PFA

SHR EE G AN ESH BI O - T E C H (I ND I A) L I M I TED CIN: L70101WB1982PLC121196 Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR, KAMDHENU BUILDING, KOLKATA -700016 Email: shreeganeshbiotechindialtd@gmail.com Website: www.shreeganeshbiotech.bar Date: 02.11.2026 To, To, To, Listing Department, The Secretary, Head - Listing BSE Limited, . The Calcutta Stock Exchange Ltd, Metropolitan Stock P J Tower, Dalal Street 7, Lyons Range, Exchange of India Limited Mumbai-400001 Kolkata - 700001 Vibgyor Towers, 4th floor, Plot Noe 62, Opp. Trident Hotel Bandra Kurla Complex, Bandra (E) Mumbai - 400098 Scrip Code: 539470 Scrip Code: 29221 Scrip Code-SHREEGANES Subject: Outcome of Board Meeting held on 02nd November 2026. Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Monday 02nd November 2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September, 2026. The board meeting commented at 04:45 PM and concluded at 05:15 PM Please take the above intimation in your records. Thanking You. Yours Faithfully, FOR, SHREE GANESH BIO-TECH (INDIA)LIMITED AMAN PATEL WHOLETIME DIRECTOR DIN NO.: 08483544 Shree Ganesh Biotech (India) Ltd CIN:- L70101WB1982PLC121196 Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020 Email:- shreeganeshbiotechindialtd@gmail.com Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2026 Quarter Ended Six Months Ended (Rs. In lacs) Year Ended 31 Sl no. Particulars 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 Mar 2026 (Refer Notes Below) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 INCOME (a) Revenue From Operation 16.00 142.99 76.74 158.99 215.10 497.05 (b) Other Income 32.27 32.01 41.01 64.28 82.54 147.22 Total Income from Operations (Net) 48.28 175.00 117.76 223.28 297.65 644.27 2 EXPENSES - (a) Cost of material consumed 28.03 186.67 111.75 214.70 223.72 5 05.57 (b) Changes in inventories of finished goods, work-in-progress, - - - - - - and stock-in-trade (c) Employee benefit expense 3.92 5.85 3.35 9.77 4.78 1 6.48 (d) Finance Costs - - - - - - (e) Depreciation and amortization expense - - - - 0 .05 (f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing 24.41 39.81 1.24 64.22 35.03 7 0.75 operations to be shown separately) Total Expenses 56.36 232.32 116.34 288.68 263.53 5 92.86 3 Profit / (Loss) from operations before exceptional items ( 8.08) (57.32) 1.41 ( 65.40) 34.11 5 1.42 Tax (1-2) 4 Exceptional Items - - - - - - 5 Profit / (Loss) before Tax (3 ± 4) ( 8.08) (57.32) 1.41 ( 65.40) 34.11 5 1.42 6 Tax Expense - - - - - 1 3.65 7 Net Profit / (Loss) after Tax (5 - 6) ( 8.08) (57.32) 1.41 ( 65.40) 34.11 3 7.76 8 Other Comprehensive Income (net of tax ) - - - - - - 9 Total Comprehensive Income for the period (7 ± 8) ( 8.08) (57.32) 1.41 ( 65.40) 34.11 3 7.76 10 Paid-up equity share capital (Face Value of Rs.1/- each) 3,986.24 3,986.24 3,986.24 3,986.24 3,986.24 3 ,986.24 11 Other Equity - - - - - 2 ,377.10 12 Earnings Per Share (of Rs. 1/- each) (not annualised): (a) Basic ( 0.00) (0.01) 0.00 ( 0.02) 0.01 0 .01 (b) Diluted ( 0.00) (0.01) 0.00 ( 0.02) 0.01 0 .01 Shree Ganesh Biotech (India) Ltd CIN:- L70101WB1982PLC121196 Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020 Email:- shreeganeshbiotechindialtd@gmail.com (Rs. in Lakhs) Standalone Statement of Assets and Liabilities As at 30th September, 2026 As at 31st March, 2026 Particulars Un-Audited Audited A ASSETS 1 Non-current assets Property, plant and equipment 0.13 0.13 Capital work-in-progress - - Other intangible assets - - Investments in subsidiaries, associates and joint ventures - - Financial assets Investments 915.00 915.00 Loans 4,213.23 4,274.88 Other financial assets - - Income Tax assets (net) - - Deferred tax assets (net) - - Other non-current assets - - Sub-total - Non-Current Assets 5,128.36 5,190.01 2 Current assets Inventories 2,282.06 1,173.10 Financial assets Investments - - Trade receivables - - Cash and cash equivalents 1.10 0.97 Bank balances other than Cash and Cash equivalents above - - Loans, Current - - Other financial assets 0.52 16.21 Other current assets - - Assets classified as held for sale - - Sub-total - Current Assets 2,283.68 1,190.28 TOTAL - ASSETS 7,412.04 6,380.29 B EQUITY AND LIABILITIES 1 Equity Equity Share capital 3,986.24 3,986.24 Other equity 2,311.70 2,377.10 Sub-total - Shareholders' funds 6,297.94 6,363.34 2 LIABILITIES Non-current liabilities Financial liabilities Borrowings, non-Current - - Provisions - - Income tax liabilities (net) - - Other non-current liabilities - - Sub-total - Non-current liabilities - - 3 Current liabilities Financial liabilities - Borrowings, Current 1,100.00 - Trade payables, Current - - Other financial liabilities - - Other current liabilities 0.45 3.30 Provisions 13.65 13.65 Current tax liabilities (net) - - Sub-total - Current liabilities 1,114.10 16.95 TOTAL - EQUITY AND LIABILITIES 7,412.04 6,380.29 Shree Ganesh Biotech (India) Ltd CIN:- L70101WB1982PLC121196 Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020 Email:- shreeganeshbiotechindialtd@gmail.com Notes: 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 02, 2026. 2 The Statutory Auditors have carried out a limited review of the above financial result. 3 Company has only one segment and hence no separate segment result has been given. 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary. 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 6 Provison for Taxation if any will be made at year end. By order of the Board For, Shree Ganesh Biotech (India) Ltd Place : Kolkata Aman Patel Date : 02nd November, 2026 Wholetime Director Shree Ganesh Biotech (India) Ltd CIN:- L70101WB1982PLC121196 Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020 STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2026 (Rs. in Lakhs, unless otherwise stated) 30.09.2026 30.09.2025 Particulars Rupees Rupees A. CASH FLOW FROM OPERATING ACTIVITIES: Profit before tax - 65.40 34.11 Adjustment For : Share of (profit)/loss from investment in partnership firm - - Depreciation/amortization on continuing operation - - Interest expenses - - Operating profit before working capital changes - 65.40 34.11 Movement in Working Capital : Increase/(decrease) in Inventory - 1 ,108.96 - Increase/(decrease) in Trade receivables - - 1 32.36 Increase/(decrease) in Short Term Loan & Advances - - Increase/(decrease) in Current Liabilities - 2 .85 - 1 2.30 Increase/(decrease) in Trade Payable - - Increase/(decrease) in Other Current Assets 15.69 - Direct taxes paid (net of refunds) - 42.36 Net Cash Flow from Operating Activities(A) - 1 ,161.52 - 68.18 B. CASH FLOW FROM INVESTING ACTIVITIES Investments /withdrawl in Partnership Firm - - Purchase / Sale of Fixed Assets - - Increase/(decrease) in Long Term Loan & Advances 61.65 - 69.30 Net Cash Flow from Invesing Activities(B) 61.65 - 69.30 C. CASH FLOW FROM FINANCING ACTIVITIES Proceed (Repayment) from long term borrowing - - Proceed (Repayment) from short term borrowing 1,100.00 1 43.18 Proceed from Preferenital Warrants - Net Cas [Showing first 8,000 characters — download PDF for full document]